SCHEMBL2175248

SCHEMBL2175248

NC(=O)OC1(c2ccc(NC(=O)OCc3ccccc3)cc2)CCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.54
MAPT P10636 2/20 0.54
KDM1A O60341 4/20 0.53
MAOA P21397 3/20 0.53
MAOB P27338 2/20 0.53
RCOR1 Q9UKL0 3/20 0.52
POLB P06746 1/20 0.51
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TSHR P16473 1/20 0.47
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ROCK2 O75116 1/20 0.46
MGLL Q99685 1/20 0.46
MMP2 P08253 2/20 0.44
MMP9 P14780 2/20 0.44
KDM1B Q8NB78 1/20 0.43
TGM2 P21980 2/20 0.42
PDE3B Q13370 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175244 0.79 POLB (0.53) TP53MAPTKDM1AMAOAMAOB
SCHEMBL26135641 0.76 AKR1C1 (0.44)
Benzyl Phenylcarbamate SCHEMBL1222943 0.75 POLB (0.78) TP53MAPTKDM1AMAOAMAOB
SCHEMBL6607260 0.75 NPC1 (0.55) TP53MAPTKDM1AMAOAMAOB
SCHEMBL15777029 0.74 TP53 (0.67) TP53MAPTKDM1AMAOAMAOB
SCHEMBL3803479 0.74 L3MBTL1 (0.47) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL7663567 0.74 POLB (0.68) TP53MAPTKDM1AMAOAMAOB
SCHEMBL1707562 0.74 POLB (0.68) TP53MAPTKDM1AMAOAMAOB
SCHEMBL1870929 0.74 POLB (0.71) TP53MAPTKDM1AMAOAMAOB
SCHEMBL6614111 0.74 POLB (0.50) TP53MAPTKDM1AMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3189036-B1 COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS ARQULE INC (US) 2023-07-19 EP disclosed
CN-111494378-A Compositions and methods for treating proliferative disorders 艾科尔公司 2020-08-07 CN disclosed
CN-107074769-B Compositions and methods for treating proliferative disorders 艾科尔公司 2020-04-07 CN disclosed
US-9949981-B2 Compositions and methods for treating proliferation disorders ARQULE, INC. (US) 2018-04-24 US disclosed
EP-3189036-A1 COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS ArQule, Inc. (US) 2017-07-12 EP disclosed
WO-2016037044-A1 COMPOSITIONS AND METHODS FOR TREATING PROLIFERATION DISORDERS ARQULE, INC. (US) 2016-03-10 WO disclosed
US-20160067260-A1 Compositions and Methods for Treating Proliferation Disorders ARQULE, INC. 2016-03-10 US disclosed
EP-2519522-B1 SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS ARQULE INC (US) 2014-09-24 EP disclosed
EP-2519522-A2 SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS ArQule, Inc. (US) 2012-11-07 EP disclosed
WO-2011082270-A2 SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS ARQULE. INC. (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160067260-A1 Compositions and Methods for Treating Proliferation Disorders MKI67, HRAS, VHL TP53 6/4885MAPT 3746/4885KDM1A 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.